Itonic Holdings Ltd. (NASDAQ:ITOC) Stock Short Interest Climbs 228.6%

Itonic Holdings Ltd. (NASDAQ:ITOC) was the target of a significant growth in short interest in the month of September. As of September 30th, there was short interest totaling 206,400 shares, a growth of 228.6% from the September 15th total of 62,815 shares. Based on an average daily volume of 1,701,703 shares, the short-interest ratio is currently 0.1 days. Currently, 19.4% of the shares of the company are sold short.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded Itonic from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, September 24th. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Itonic Stock Up 1.2%

Shares of ITOC stock traded up $0.05 during trading on Friday, reaching $4.07. 14,110 shares of the company’s stock were exchanged, compared to its average volume of 67,873. Itonic has a twelve month low of $3.42 and a twelve month high of $18.40. The firm’s fifty day moving average price is $4.68 and its 200-day moving average price is $4.95.

Itonic (NASDAQ:ITOC) last released its quarterly earnings data on Wednesday, September 30th. The company reported ($0.75) EPS for the quarter. The business had revenue of $0.05 million for the quarter.

Itonic Company Profile

iTonic Holdings Ltd., a healthcare solutions provider, develops and commercializes treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a radioactive particle implantation, a radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company offers FTTPS, a treatment planning system for treating various malignant tumors, which could determine the target volume, prescription dose, and dose limitation to protect organs at risks and produce dose distribution plan for brachytherapy for cancer patients.